An Open Label ,Phase I, 2-way Crossover Study Evaluating the Pharmacokinetics of Prana P1 THC Activated Capsules

Exclusion criteria

• Current major Axis I psychiatric disorder for which the participant is currently receiving treatment or which would make study compliance an issue.
• Any condition or therapy that, in the opinion of the investigator, may be significantly worsened by the exposure to marijuana.
• Acute disease at the time of enrolment (i.e., presence of a moderate or severe illness or infection with or without a fever).
• Febrile illness (oral temperature \>37.6° C at the time of drug administration).
• Unstable chronic illnesses.
• Chronic liver, renal or inflammatory bowel disease or collagen vascular disease.
• Clinically significant elevation of Alanine transaminase(ALT) and/or Aspartate transaminase (AST).
• Active neurological disorder.
• Clinically significant uncontrolled illness or clinically significant surgery within 4 weeks prior to administration of study drug.
• Cancer within the previous 5 years, other than squamous cell or basal cell carcinoma of the skin.
• Difficulty to swallow study medication.
• Smoking more than 25 cigarettes per day.
• History of any clinical laboratory abnormality deemed significant by the Principal Investigator.